Resmed Inc Stock (RMD) Moved Up by 3.05% on Sep 15: A Full Analysis

Resmed Inc (RMD) moved up by 3.05%. The Healthcare Services & Equipment sector is down by 0.06%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Thermo Fisher Scientific Inc (TMO) up 3.40%; Unitedhealth Group Inc (UNH) down 1.51%; Stryker Corp (SYK) down 0.60%.

What is driving Resmed Inc (RMD)’s stock price up today?

ResMed experienced notable upward momentum driven primarily by a high-profile analyst upgrade. RBC Capital Markets raised its rating on the medical device maker to Outperform from Sector Perform while lifting its price target. Analysts highlighted an undemanding valuation following recent price adjustments, noting that market pricing reflects overly pessimistic assumptions regarding long-term competitive dynamics. The positive rating adjustment acted as an immediate catalyst, boosting buying interest and instilling renewed confidence among institutional investors.

Fueling the constructive sentiment is ResMed's sharpened focus on capital return and portfolio optimization. The company recently announced an accelerated share repurchase program financed by proceeds from the sale of its MatrixCare software business, while simultaneously expanding its dividend payout. This divestiture allows management to concentrate resources on higher-growth core software and respiratory platforms. Institutional investors view the aggressive buyback activity and disciplined fiscal strategy under newly established guidance as a strong signal of management's confidence in underlying earnings power.

Underlying business performance continues to support a positive outlook within the global obstructive sleep apnea market. Robust revenue expansion across global devices and mask categories underscores ResMed's sustained market leadership. Furthermore, regulatory disruptions facing key industry competitors, including class 1 device recalls for rival products, provide operational tailwinds that support ResMed's market share momentum. While intraday volatility reflects broader healthcare sector rebalancing and macroeconomic pressures, solid fundamental cash flow and enhanced capital management position the company favorably for institutional investors.

Technical Analysis of Resmed Inc (RMD)

Technically, Resmed Inc (RMD) shows a MACD (12,26,9) value of -3.446, indicating a neutral signal. The RSI at 56.362 suggests neutral condition and the Williams %R at 47.406 suggests neutral condition. Please monitor closely.

Media Coverage of Resmed Inc (RMD)

In terms of media coverage, Resmed Inc (RMD) shows a coverage score of 17, indicating a very low level of media attention. The overall market sentiment index is currently in extremely bullish zone.

Fundamental Analysis of Resmed Inc (RMD)

Resmed Inc (RMD) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $5.65B, ranking 23 in the industry. The net profit is $1.52B, ranking 12 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Hold, with an average price target of $248.92, a high of $320.00, and a low of $175.00.

More details about Resmed Inc (RMD)

Company Specific Risks:

• Astral Ventilator Field Safety Suspension: The suspension of sales for the Astral ventilator line following a field safety notification regarding device leaks triggered a $42 million GAAP charge and an estimated $75 million revenue headwind for fiscal 2027, creating a $0.15 per share earnings drag.
• Fiscal 2027 Guidance Shortfall: ResMed's management issued full-year fiscal 2027 core revenue growth guidance of 5% to 7% ($5.75 billion to $5.85 billion), falling below consensus expectations of $5.92 billion and driving concerns over decelerating organic demand.
• Threat of Competitive Market Re-Entry: Institutional analysts cite lingering market share and pricing risk as primary competitor Philips Respironics advances regulatory remediation steps to re-enter the U.S. sleep apnea market.
• Operating Margin Compression: ResMed reported a contraction in operating margins to 30.7% (down from 33.7% in the prior-year period) due to elevated supply chain expenses and higher R&D overhead, eroding operational leverage.